TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05710757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release
Description: Myofascial release (MFR) is a technique that involves applying gentle sustained pressure into the myofascial connective tissue restrictions to eliminate pain and restore motion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood flow restriction
Description: Blood flow restricted (BFR) exercise is the brief and non-continuous blockage of venous blood flow using a device that restricts the flow of blood while exercising. This technique is used to produce hypertrophy (muscle growth) and strength responses while exercising at a lighter load than traditionally required to produce a similar response.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: blood flow restriction
Description: Blood flow restricted (BFR) exercise is the brief and non-continuous blockage of venous blood flow using a device that restricts the flow of blood while exercising. This technique is used to produce hypertrophy (muscle growth) and strength responses while exercising at a lighter load than traditionally required to produce a similar response.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: myofascial release
Description: Sham MFR.
Study: NCT04553016

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: IM vaccination with ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVconsv4

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM administration of 0.9% sterile sodium chloride solution
Study: NCT05926349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andexanet alfa
Description: Andexanet is a recombinant version of human FXa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: As per the label of the chosen usual care product(s) and/or usual care standards.
Study: NCT05757856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDX-3315 and NDX-3324
Description: Oral solution
Study: NCT06102200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT4CBT
Description: This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT4CBT
Description: This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RC
Description: Peer recovery coaching services involve a form of nonclinical, peer support aimed at helping individuals with substance use disorders to achieve and maintain recovery. Recovery coaches are individuals with experience with substance use and successful recovery. In addition to their lived experience, recovery coaches obtain formal training on substance use coaching and receive ongoing supervision. The recovery coaches use an assertive engagement approach to provide holistic, person-centered, and strength-based support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sandard of care
Description: Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly, bi-weekly or monthly visits (at the discretion of the provider) in-person or virtually. This condition will be matched with the other conditions in terms of the number of research visits.
Study: NCT05007496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: DCL previously loaded with varying quantity of S-protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: DCL previously loaded with varying quantity of S-protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: DCL previously loaded with varying quantity of S-protein
Study: NCT04173260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine 6 MG
Description: Increasing doses of Deutetrabenazine
Study: NCT04762043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental System: MyoVoice
Description: Person-centric augmentative and alternative communication (AAC) system comprising a user-specific set of wearable sensors for capturing articulatory muscle activity and mobile software that provides real-time audible speech outputs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reference System: Electrolarynx
Description: Hand-operated electromechanical device that operates as an artificial larynx to enable a person after laryngectomy to produce speech.
Study: NCT05014464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib 250mg po bid Aectinib 600mg po bid Lorlatinib 100mg po qd Brigatinib, 90mg po qd for one week and than 180mg po qd forever Pemetrexed 500mg/m2
Study: NCT06504602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Virtual Reality
Description: Active virtual reality group will play a game through a virtual environment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive Virtual Reality
Description: Passive virtual reality group will watch a movie through a virtual environment.
Study: NCT06501768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: Escalation genistein dosing, followed by wash-out period
Study: NCT05289180

Intervention type: OTHER
Intervention: Questionnaires
Description: A questionnaire will be administered post-procedure to assess for pain and anxiety. This questionnaire will be administered by study personnel delegated to administer questionnaires, namely the study coordinator or PI.
Study: NCT04508478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Aerobic training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: Resistance training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control physical exercise
Description: Control physical exercise
Study: NCT05602883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Music is played for 30 minutes to the pregnant woman who is hospitalized due to the threat of premature birth.
Study: NCT05679479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meplazumab for injection
Description: Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
Study: NCT04853511

Intervention type: DEVICE
Intervention: OCT-FLIM (optical coherence tomography-fluorescence life time)
Description: comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular catheter imaging followed by serial 18F-FDG-PET/CT imaging
Study: NCT05679479

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% normal saline
Study: NCT05195125

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Peritoneal Resuscitation
Description: Direct peritoneal resuscitation involves the abdominal infusion and drainage of a peritoneal dialysate in high-risk liver transplant patients, for up to 24 hours after surgery.
Study: NCT05748756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enucleation and filling by Bone marrow aspirate
Description: The iliac crest is palpated along its widest part forming the iliac tubercle ( 5-6 cm posterior to the anterior superior iliac spine), then a 5 mm incision is made 3-4 cm posterior to the ASIS directly on the crest.~The needle is advanced between the outer and inner plates of the ileum for a 4-6 cm into the cancellous bone and 10 ml of bone marrow is aspirated.~Bone marrow aspirate is processed by a dual centrifugation technique.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional enucleation only
Description: patients were treated conventionally by enucleation and plain collagen sponge only.
Study: NCT06101979

Intervention type: DEVICE
Intervention: Fortiva Tissue Matrix
Description: Acellular Dermal Matrix used in hernia surgery
Study: NCT04757064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard rehabilitation protocol
Description: they will receive knee flexion exercises and increase the extensor strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard rehabilitation protocol
Description: they will receive knee flexion exercises and increase the extensor strength
Study: NCT05014464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib 250mg po bid Aectinib 600mg po bid Lorlatinib 100mg po qd Brigatinib, 90mg po qd for one week and than 180mg po qd forever Pemetrexed 500mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib 250mg po bid Aectinib 600mg po bid Lorlatinib 100mg po qd Brigatinib, 90mg po qd for one week and than 180mg po qd forever Pemetrexed 500mg/m2
Study: NCT05612672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GeoHAI
Description: A Geographic healthcare-associated infection (HAI) visualization and assessment tool (GeoHAI) which uses spatio-temporal Bayesian models to identify clusters of National Healthcare Safety Network (NHSN)-defined hospital onset Clostridium difficile (CDI) and multidrug resistant organisms (MDRO), and predict potential high risk areas given hospital and patient risk factors.
Study: NCT04963543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID123238
Description: Lubricant applied to the ocular surface
Study: NCT05769010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811: intravenous
Study: NCT06034951

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Compleat 1.5 HP
Description: Patients well established and stable on an enteral tube feed. This group will act as their own controls and switched to the new tube feed.
Study: NCT04776187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadodiamide
Description: Gadodiamide Injection(OMNISCAN™)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteric Acid Meglumine Salt
Description: Gadoteric Acid Meglumine Salt Injection(Jia Di Xian™)
Study: NCT05769010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab: intravenous
Study: NCT06546774

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: In the study group, patients will receive melatonin supplementation for at least two months prior to IVF cycles
Study: NCT05597748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Herbst Approach
Description: A modified hybrid Herbst appliance approach (same hybrid Herbst appliance approach but with the addition of temporary anchorage devices (TADs) in both arches) will be used (alternative treatment). In the upper arch, the TADs would be inserted in the paramedical palatal area. In the lower arch, they would be inserted buccally between the roots of the lower second premolar and the first permanent molar. Elastomeric chains will be used to link these TADs to the first molars in the upper arch and to a buccal bottom on the lower canines. Upper brackets will be initially bonded and upper incisors proclined until normal inclination values are attained.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Herbst Approach
Description: A modified hybrid Herbst appliance approach (same hybrid Herbst appliance approach but with the addition of temporary anchorage devices (TADs) in both arches) will be used (alternative treatment). In the upper arch, the TADs would be inserted in the paramedical palatal area. In the lower arch, they would be inserted buccally between the roots of the lower second premolar and the first permanent molar. Elastomeric chains will be used to link these TADs to the first molars in the upper arch and to a buccal bottom on the lower canines. Upper brackets will be initially bonded and upper incisors proclined until normal inclination values are attained.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Herbst Approach
Description: A hybrid Herbst appliance approach will be used (current available conventional treatment). The upper jaw component will be a maxillary expander secured on the first molar bands. The lower arch would have an uncemented lower acrylic full-coverage splint-type. In between Herbst-type pistons will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Herbst Approach
Description: A hybrid Herbst appliance approach will be used (current available conventional treatment). The upper jaw component will be a maxillary expander secured on the first molar bands. The lower arch would have an uncemented lower acrylic full-coverage splint-type. In between Herbst-type pistons will be used.
Study: NCT06291415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: Syk inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: Syk inhibitor
Study: NCT06173102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial Orthosis
Description: Early versus usual reception of orthosis.

Intervention type: DEVICE
Group type: OTHER
Intervention: Cranial Orthosis
Description: Early versus usual reception of orthosis.
Study: NCT04920630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy - Insomnia (CBT-I)
Description: CBT-I will be delivered via 5 weekly virtual group therapy sessions. Session content is manualized and adapted from existing CBT-I protocols to be relevant to a virtual adolescent group and will include: Session 1 - Introduction of group members, group rules, psychoeducation regarding sleep, and instructions on completion of sleep log. Session 2 - Review sleep log, sleep hygiene, relaxation training, and stimulus control. Session 3 - Review sleep log, sleep restriction, and cognitive strategies (positive self-statements, worry management). Session 4 - Review sleep log and sleep restriction, and problem-solving barriers. Session 5 - Maintenance and relapse prevention.
Study: NCT06089928

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vertical augmentation
Description: sandwich osteotomy with an Interpositional inlay graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vertical augmentation
Description: sandwich osteotomy with an Interpositional inlay graft
Study: NCT04837131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib 4 mg capsule taken orally on days 1, 8, and 15 of a 28-day treatment cycle repeated for 6 cycles
Study: NCT06509763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECGI system during LBBP implant
Description: ECGI system to create non-invasive ventricular maps during the screwing steps of the LBBP electrode
Study: NCT06395454

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Shorten antibiotics duration based on procalcitonin test levels
Description: procalcitonin test will be taken on day 1 of recruitment as baseline, test done on day 5 will decide whether antibiotics will be withheld, followed by day 7 to determine rate of reinfection.
Study: NCT05087212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor + G-CSF
Description: subcutaneous (SC) injection
Study: NCT06232811

Intervention type: BEHAVIORAL
Intervention: Assessment
Description: Sensory processing skills of children in the preterm and term groups will be evaluated. Additionally, the attachment between mother and baby will be evaluated.

Intervention type: BEHAVIORAL
Intervention: Assessment
Description: Sensory processing skills of children in the preterm and term groups will be evaluated. Additionally, the attachment between mother and baby will be evaluated.
Study: NCT06304753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telebot
Description: This is a mini-program based on a personal messenger, which is controlled by text commands in a chat on the question-answer principle. It allows us to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) related to heart failure.~Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 6 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.
Study: NCT06506188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LINK model
Description: The LINK model includes four elements:~(1) linking postpartum HIV testing and PrEP services to early infant vaccination, (2) screening for HIV risk among those who test negative for HIV at the early infant vaccination visit, (3) male partner engagement to support status awareness within couples and PrEP persistence, and (4) community-facility linkage (CFL) peer mom for ongoing support of breastfeeding women using PrEP and follow-up of breastfeeding women who disengage from PrEP care.
Study: NCT06267469

Intervention type: DEVICE
Group type: OTHER
Intervention: Thermoplastic orthosis
Description: The use of the author's orthosis is aimed at correcting the anatomical alignment of the MP (metacarpophalangeal) joints, IP (interphalangeal) by properly tensioning the central extensor band and the lateral bands of the thumb's extensor apparatus. It should significantly increase the mobility of the hand in connection with improving hand grip and reducing pain.

Intervention type: DEVICE
Group type: OTHER
Intervention: Thermoplastic orthosis
Description: The use of the author's orthosis is aimed at correcting the anatomical alignment of the MP (metacarpophalangeal) joints, IP (interphalangeal) by properly tensioning the central extensor band and the lateral bands of the thumb's extensor apparatus. It should significantly increase the mobility of the hand in connection with improving hand grip and reducing pain.

Intervention type: DEVICE
Group type: OTHER
Intervention: Thermoplastic orthosis
Description: The use of the author's orthosis is aimed at correcting the anatomical alignment of the MP (metacarpophalangeal) joints, IP (interphalangeal) by properly tensioning the central extensor band and the lateral bands of the thumb's extensor apparatus. It should significantly increase the mobility of the hand in connection with improving hand grip and reducing pain.

Intervention type: DEVICE
Group type: OTHER
Intervention: Thermoplastic orthosis
Description: The use of the author's orthosis is aimed at correcting the anatomical alignment of the MP (metacarpophalangeal) joints, IP (interphalangeal) by properly tensioning the central extensor band and the lateral bands of the thumb's extensor apparatus. It should significantly increase the mobility of the hand in connection with improving hand grip and reducing pain.

Intervention type: DEVICE
Group type: OTHER
Intervention: Thermoplastic orthosis
Description: The use of the author's orthosis is aimed at correcting the anatomical alignment of the MP (metacarpophalangeal) joints, IP (interphalangeal) by properly tensioning the central extensor band and the lateral bands of the thumb's extensor apparatus. It should significantly increase the mobility of the hand in connection with improving hand grip and reducing pain.

Intervention type: DEVICE
Group type: OTHER
Intervention: Thermoplastic orthosis
Description: The use of the author's orthosis is aimed at correcting the anatomical alignment of the MP (metacarpophalangeal) joints, IP (interphalangeal) by properly tensioning the central extensor band and the lateral bands of the thumb's extensor apparatus. It should significantly increase the mobility of the hand in connection with improving hand grip and reducing pain.
Study: NCT05482529

Intervention type: OTHER
Intervention: Integrative omics
Description: Integrative omics such as RNA-sequencing,ATAC-seq(Assay for Transposase-Accessible Chromatin using sequencing), CUT\&Tag（ Cleavage Under Targets and Tagmentation）to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.
Study: NCT05571670

Intervention type: DRUG
Intervention: Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
Description: Participants will be treated with PI3K/AKT/mTOR inhibitors by their treating oncologist based on standard of care. This study will prospectively monitor bile acids and parameters of insulin resistance before and during treatment with these drugs.